Repligen Plans NDA for Imaging Agent on Positive Phase III Data
Repligen Corp. reported that its imaging agent RG1068, a synthetic human secretin, showed statistically significant improvements in detecting pancreatic disease via magnetic resonance imaging, and the Waltham, Mass.-based firm plans to meet with the FDA to discuss a new drug application filing.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.